REG - Celadon Pharma. PLC - Publication of Annual Report and Notice of AGM

Celadon PharmaceuticalsAnnouncement

05/06/2023 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230605:nRSE6904Ba&default-theme=true

RNS Number : 6904B  Celadon Pharmaceuticals PLC  05 June 2023

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Company")

 

Publication of Annual Report and Notice of Annual General Meeting

 

London, 5 June 2023 - Celadon Pharmaceuticals Plc, a leading UK based
pharmaceutical company focused on the development and supply of natural
cannabis-based medicines, announces that copies of the 2022 Annual Report and
Accounts, together with its Notice of 2023 Annual General Meeting ("AGM"),
were posted to shareholders today and are available for viewing on the
Company's website www.celadonpharma.com (http://www.celadonpharma.com) .

 

The Company will be holding its AGM at 12 noon on Thursday 29 June 2023 at the
offices of CMS Cameron McKenna Nabarro Olswang LLP, Cannon Place, 78 Cannon
Street, London EC4N 6AF.

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Jonathan Turner

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam/Andrew Potts / Patrick Dolaghan            +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil

 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility is EU-GMP approved and comprises indoor hydroponic
cultivation, proprietary GMP extraction and manufacturing and an analytical
and R&D laboratory. Celadon's Home Office licence allows for the
commercial supply of its GMP pharmaceutical cannabis product. The Company's
subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using
cannabis based medicinal products to treat chronic pain in the UK. Celadon
also has a minority interest in early-stage biopharma Kingdom Therapeutics
which is developing a licenced cannabinoid medicine to treat children with
Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAXELFBXQLZBBZ